Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system

Radioactive-iodine (RAI) therapy is typically unprevailing as anaplastic thyroid cancer (ATC) management, owing to the decrease in the endogenous sodium iodide symporter (NIS) expression. Therefore, new strategies for NIS re-induction are required to improve the efficacy of RAI therapy in ATC. In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Ji Min, Kalimuthu, Senthilkumar, Gangadaran, Prakash, Baek, Se Hwan, Zhu, Liya, Lee, Ho Won, Rajendran, Ramya Lakshmi, Hong, Chae Moon, Jeong, Shin Young, Lee, Sang-Woo, Lee, Jaetae, Ahn, Byeong-Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805537/
https://www.ncbi.nlm.nih.gov/pubmed/29467951
http://dx.doi.org/10.18632/oncotarget.24159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805537/
https://www.ncbi.nlm.nih.gov/pubmed/29467951
http://dx.doi.org/10.18632/oncotarget.24159

Ejemplares similares